MUMBAI, India, March 13 -- Intellectual Property India has published a patent application (202611009865 A) filed by Swami Vivekananda Subharti University, Meerut, Uttar Pradesh, on Jan. 30, for 'a system and method for delivering bioelectric-responsive, circadian-timed sirna-loaded lipid nanodroplets for long-acting treatment of resistant hypertension.'
Inventor(s) include Mr. Nishant Gaurav; Dr. Sumita Singh; and Mr. Vishal Kumar Biswkarma.
The application for the patent was published on March 13, under issue no. 11/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to bioelectric-responsive, circadian-timed siRNA-loaded lipid nanodroplets designed for long-acting treatment of resistant hypertension. The disclosed system comprises dual-phase lipid nanodroplets featuring a hydrophobic core encapsulating siRNA targeted against hypertension-associated genes, including AGT, ACE, NEDD4L, and NR3C2, and an adaptive lipid shell formulated with ionizable, phospholipid, cholesterol, and circadian-responsive components. Upon administration, the nanodroplets exhibit selective accumulation in renal and vascular tissues through responsiveness to endogenous bioelectric gradients. Following cellular uptake, protonation of ionizable lipids enables endosomal escape and cytoplasmic release of siRNA, resulting in RISC-mediated gene silencing and sustained suppression of RAAS-related pathways. The circadian-timed architecture enables synchronized release of siRNA aligned with physiological fluctuations, providing extended therapeutic action lasting one to six months. The invention offers a targeted, stable, and long-acting gene-silencing platform that overcomes limitations of conventional antihypertensive therapies and reduces dosing frequency in patients with resistant hypertension."
Disclaimer: Curated by HT Syndication.
